Abstract
Type 2 diabetes mellitus (T2DM) accounts for 90%–95% of all diabetes cases. The overarching goal in caring for patients with T2DM is to prevent microvascular and macrovascular complications with glycemic control. Several studies such as UKPDS, DCCT, and EDIC have been performed to evaluate the effects of glucose control on tissue complications in patients with diabetes. In recent diabetes trials including ACCORD, ADVANCE, VADT, BARI 2D, and ORIGIN, intensive glucose control did not prevent macrovascular complications in older patients with long-standing diabetes with either cardiovascular disease or risk factors for cardiovascular disease. In fact, intensive therapy was associated with increased mortality in the ACCORD trial. Although no clear macrovascular benefit was seen in these trials, analyses of earlier studies in younger patients with type 1 and type 2 diabetes have suggested a significant benefit of intensive glycemic control in patients with a shorter duration of diabetes and less vasculopathy. In the UKPDS, the incidence of microvascular disease, particularly retinopathy, was reduced significantly with intensive glucose control, but in the more recent trials (ACCORD, ADVANCE, VADT, ORIGIN) the benefit was relatively modest and limited to reduced proteinuria. Perhaps the most important message from the above trials is to optimize control of cardiovascular risk factors. Although the goal HbA1c to prevent microvascular and macrovascular complications, per the American Diabetes Association, is less than 7%, hypoglycemia should be avoided as it can increase the risk for severe cardiovascular events.
Keywords: ACCORD, ADVANCE, BARI 2D, diabetes trials, intensive glycemic control, macrovascular disease, ORIGIN, VADT.
Current Diabetes Reviews
Title:An Insight into the Recent Diabetes Trials: What is the Best Approach to Prevent Macrovascular and Microvascular Complications?
Volume: 9 Issue: 5
Author(s): Manige Konig, Elizabeth Mary Lamos, Stephanie Aleskow Stein and Stephen N. Davis
Affiliation:
Keywords: ACCORD, ADVANCE, BARI 2D, diabetes trials, intensive glycemic control, macrovascular disease, ORIGIN, VADT.
Abstract: Type 2 diabetes mellitus (T2DM) accounts for 90%–95% of all diabetes cases. The overarching goal in caring for patients with T2DM is to prevent microvascular and macrovascular complications with glycemic control. Several studies such as UKPDS, DCCT, and EDIC have been performed to evaluate the effects of glucose control on tissue complications in patients with diabetes. In recent diabetes trials including ACCORD, ADVANCE, VADT, BARI 2D, and ORIGIN, intensive glucose control did not prevent macrovascular complications in older patients with long-standing diabetes with either cardiovascular disease or risk factors for cardiovascular disease. In fact, intensive therapy was associated with increased mortality in the ACCORD trial. Although no clear macrovascular benefit was seen in these trials, analyses of earlier studies in younger patients with type 1 and type 2 diabetes have suggested a significant benefit of intensive glycemic control in patients with a shorter duration of diabetes and less vasculopathy. In the UKPDS, the incidence of microvascular disease, particularly retinopathy, was reduced significantly with intensive glucose control, but in the more recent trials (ACCORD, ADVANCE, VADT, ORIGIN) the benefit was relatively modest and limited to reduced proteinuria. Perhaps the most important message from the above trials is to optimize control of cardiovascular risk factors. Although the goal HbA1c to prevent microvascular and macrovascular complications, per the American Diabetes Association, is less than 7%, hypoglycemia should be avoided as it can increase the risk for severe cardiovascular events.
Export Options
About this article
Cite this article as:
Konig Manige, Lamos Mary Elizabeth, Stein Aleskow Stephanie and Davis N. Stephen, An Insight into the Recent Diabetes Trials: What is the Best Approach to Prevent Macrovascular and Microvascular Complications?, Current Diabetes Reviews 2013; 9 (5) . https://dx.doi.org/10.2174/15733998113099990077
DOI https://dx.doi.org/10.2174/15733998113099990077 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
Call for Papers in Thematic Issues
Advancing Diabetic Wound Healing: Mechanisms and Interventions
In recent years, diabetic wounds have become a global health concern with the increase in the incidence of diabetes. Diabetic wounds are a kind of chronic and refractory ulcer. It is generally due to the microcirculatory disturbances and the reduced levels of endogenous growth factors. Delayed cutaneous wound healing is ...read more
Oxidative and inflammatory responses in the development of secondary diabetic complications
Diabetes, along with its associated secondary complications, represents a significant global health challenge, contributing significantly to morbidity and mortality. Unhealthy lifestyle habits, reduced physical activity, environmental pollutants, and stress are pivotal factors in the onset of diabetes, particularly type-2 diabetes. Poorly managed hyperglycemia can lead to various complications, including neuropathy, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Migraine and Coronary Artery Disease: An Open Study on the Genetic Polymorphism of the 5, 10 Methylenetetrahydrofolate (MTHFR) and Angiotensin I-Converting Enzyme (ACE) Genes
Central Nervous System Agents in Medicinal Chemistry Transcranial Doppler Ultrasonography: Current Status
Current Medical Imaging Regulation of Platelet Function by Acetylation/Deacetylation Mechanisms
Current Medicinal Chemistry Experimental Strategies in Autoimmunity: Antagonists of Cytokines and their Receptors, Nanocarriers, Inhibitors of Immunoproteasome, Leukocyte Migration and Protein Kinases
Current Pharmaceutical Design Heart Failure in South Asia
Current Cardiology Reviews Therapeutic Implications of Immune-endocrine Interactions in the Critically Ill Patients
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Cardiac Metabolism in Myocardial Ischemia
Current Pharmaceutical Design Renin-Angiotensin Antagonists: Therapeutic Effects Beyond Blood Pressure Control?
Current Pharmaceutical Design Inhibitory Effects of Some Bryophytes on Glutathione-S -Transferase
Current Enzyme Inhibition Controversies of Dopamine Agonists: Somnolence, Cardiac Valvulopathy and Repetitive Behaviors
Current Drug Therapy Modulation of Retinal Arteriolar Central Reflection by APOE Genotype
Current Alzheimer Research Thyroid Hormone Ligands and Metabolic Diseases
Current Pharmaceutical Design Hemostatic Factors and the Metabolic Syndrome
Current Vascular Pharmacology Renal Protective Effect of Metabolic Therapy in Patients with Coronary Artery Disease and Diabetes: From Bench to Bed Side
Current Pharmaceutical Design Neuropeptide Y Induces Cardiomyocyte Hypertrophy <i>via</i> Attenuating miR-29a-3p in Neonatal Rat Cardiomyocytes
Protein & Peptide Letters Beta-blockers in the Perioperative Period: Are there Indications other than Prevention of Cardiac Ischemia?
Current Drug Targets Lithium and its Neuroprotective and Neurotrophic Effects: Potential Treatment for Post-Ischemic Stroke Sequelae
Current Drug Targets Therapeutic Potential of Targeting Protease Activated Receptors in Cardiovascular Diseases
Current Pharmaceutical Design Gene Delivery Strategies Targeting Stable Atheromatous Plaque
Current Pharmaceutical Design Endothelial Dysfunction in Dyslipidaemia: Molecular Mechanisms and Clinical Implications
Current Medicinal Chemistry